Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models
Propanc Biopharma announced positive preclinical and translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma models. The study results demonstrated greater than 90% mean tumor growth inhibition and a more than 2.5-fold extension in median overall survival compared to controls.
Key figures
- Drug Name
- PRP
- Gmp target
- late 2026
- Planned patients
- 30-40
- Survival extension
- 2.5-fold
- Tumor growth inhibition
- >90%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.